Stock SBFM SUNE BIOP
Add to a list
To use this feature you must be a member
Log inSign up

Financials SUNE BIOP OTC Markets

Equities

SBFM

US8677812054

Pharmaceuticals

Delayed OTC Markets
Other stock markets
 11:15:16 2021-10-05 am EDT 		5-day change 1st Jan Change
0.1175 USD -1.26% Intraday chart for SUNE BIOP +0.34% +657.96%
Apr. 19 Sunshine Biopharma Unit Receives Health Canada Approval for Biosimilar Product MT
Apr. 19 Top Premarket Decliners MT

Valuation

Fiscal Period: December 2022 2023 2024 2025
Capitalization 1 14.45 6.972 0.8537 -
Enterprise Value (EV) 1 14.45 6.972 0.8537 0.8537
P/E ratio -0.36 x -1.43 x 1.02 x 0.07 x
Yield - - - -
Capitalization / Revenue - 0.29 x 0.02 x 0.01 x
EV / Revenue - 0.29 x 0.02 x 0.01 x
EV / EBITDA - - - -
EV / FCF - - - -
FCF Yield - - - -
Price to Book - - - -
Nbr of stocks (in thousands) 226 257 994.5 -
Reference price 2 64.00 27.15 0.8584 0.8584
Announcement Date 4/4/23 3/28/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025
Net sales 1 - 24.09 44.4 100
EBITDA - - - -
EBIT 1 - -4.785 -0.237 12.06
Operating Margin - -19.86% -0.53% 12.06%
Earnings before Tax (EBT) 1 - -4.111 0.8431 12.99
Net income 1 -26.74 -4.506 0.6831 12.81
Net margin - -18.7% 1.54% 12.81%
EPS 2 -176.0 -19.00 0.8400 11.81
Free Cash Flow - - - -
FCF margin - - - -
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 4/4/23 3/28/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 5.561 5.958 7.68 7 9 12.6 15.8
EBITDA - - - - - - -
EBIT 1 -0.9896 -0.7795 -1.187 -1.293 -0.613 0.3005 1.368
Operating Margin -17.8% -13.08% -15.46% -18.47% -6.81% 2.38% 8.66%
Earnings before Tax (EBT) 1 -0.8144 -0.6105 -1.03 -1.013 -0.343 0.5705 1.629
Net income 1 -0.9021 -0.6515 -1.25 -1.053 -0.383 0.5305 1.589
Net margin -16.22% -10.94% -16.28% -15.04% -4.26% 4.21% 10.05%
EPS 2 -2.000 -4.000 -5.700 -1.040 -0.3700 0.5500 1.600
Dividend per Share - - - - - - -
Announcement Date 8/10/23 11/13/23 3/28/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025
Net Debt - - - -
Net Cash position - - - -
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - - - -
ROE (net income / shareholders' equity) - - - -
ROA (Net income/ Total Assets) - - - -
Assets 1 - - - -
Book Value Per Share - - - -
Cash Flow per Share - - - -
Capex - - - -
Capex / Sales - - - -
Announcement Date 4/4/23 3/28/24 - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for SUNE BIOP

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.8584 USD
Average target price
15 USD
Spread / Average Target
+1,647.44%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 332B
ABBVIE INC. Stock AbbVie Inc.
+4.23% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 231B
NOVARTIS AG Stock Novartis AG
+4.71% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 195B
AMGEN INC. Stock Amgen Inc.
-4.04% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SBFM Stock
  4. SBFM Stock
  5. Financials SUNE BIOP